Based on published clinical guidance · Last updated 29 October 2026
AMD is damage to the macula, the part of the retina used for sharp central vision. NEI explains that it can affect reading, recognising faces and other detailed tasks. It does not usually remove all peripheral vision, but central loss can still be disabling. An examination establishes the type and stage and checks for other causes of visual difficulty. [12]
Dry AMD involves deposits, pigment changes or areas of tissue loss; wet AMD involves abnormal vessels that leak or bleed beneath the macula. ICO describes the wet mechanism, and current AAO guidance stresses prompt assessment of active disease. The labels do not predict every person’s course, so ask what is actually present in your eye. [1][4]
AMD usually affects central vision rather than all peripheral sight, so it does not normally cause complete blindness by itself. NEI makes this distinction while recognising the serious effect of central loss on daily life. Your outlook depends on the stage and other eye conditions. Ask about treatment and visual support rather than assuming that the diagnosis has one inevitable outcome. [12]
AMD is usually painless and does not change the outward appearance of the eye, according to NHS information. Comfort therefore does not rule out active disease. New distortion or central blur still needs advice. A painful red eye, sudden major loss or a moving curtain may indicate another urgent problem and should not simply be attributed to AMD. [13]
Seek prompt eye-care advice if straight lines become newly wavy or crooked. NICE lists distortion as a change to report because wet AMD or another macular problem may need assessment. Note which eye is affected and when it began. Do not wait for the next routine appointment or rely on a previously normal grid to explain it away. [3]
Yes; a clearer eye can make a change in the other eye less obvious during ordinary activities. AAO’s Amsler instructions therefore check each eye separately while the other is covered. Home awareness supports monitoring but does not diagnose the cause. Tell an eye-care professional about any new difference, even if overall vision still seems adequate. [16]
OCT helps show the macular layers and detect fluid associated with active wet AMD. NICE recommends it when active wet disease is suspected and for monitoring treated eyes. The scan is interpreted with your sight, symptoms and examination. A reassuring image alone should not end the discussion if your visual function has changed. [3]
No; additional dye imaging depends on whether examination and OCT settle the diagnosis. NICE recommends it in selected circumstances when abnormal vessel growth remains uncertain. The purpose and relevant risks should be explained before testing. Ask what question the test is meant to answer rather than assuming that every macular assessment uses the same investigations. [3]
Yes; AAO identifies smoking as an important modifiable risk factor and recommends stopping. Smoking history also matters when choosing supplements because beta-carotene-containing products can increase lung-cancer risk in people who have smoked. Tell your clinician even if you stopped years ago. A healthy lifestyle supports care, but does not replace assessment or treatment of active disease. [4][10]
Family history can increase risk, but it does not mean you will certainly develop AMD or follow a relative’s course. NEI recommends eye examinations when risk factors are present. Routine commercial genetic testing is not needed to select standard AREDS-based supplements. Clinical examination and the stage of disease are more useful for the usual treatment discussion. [12][11]
No; benefit depends on the stage, particularly intermediate AMD or certain situations involving advanced disease in the other eye. NEI and Cochrane distinguish this from early AMD or eyes without AMD. Ask whether your findings match the groups that benefit, and discuss medicines and smoking history before starting a high-dose product. Supplements do not restore lost vision. [10][6]
It means a lower chance of progression to advanced AMD, not 25% better sight. NEI attributes the roughly 25% reduction over five years to the original AREDS formula in relevant higher-risk groups. AREDS2 then studied formula changes. Your own starting risk matters, so this is not a promise that a quarter of your vision will return or that progression cannot occur. [11]
AREDS2 uses lutein and zeaxanthin instead of beta-carotene, avoiding an important concern for current and former smokers. The AREDS2 trial and longer follow-up support that substitution. The original study did not show that simply adding every extra ingredient produced another overall benefit. Ask about an appropriate formulation rather than choosing on the basis of more ingredients or a brand claim. [8][9]
Not automatically; the tested formulation uses specific ingredients at amounts different from an ordinary multivitamin. NEI advises discussing the appropriate product and other medicines with your clinician. Avoid taking several high-dose products together without checking their contents. The supplement discussion should follow a diagnosis and stage assessment, rather than being a general response to tired eyes or concern about ageing. [10]
No; supplements do not cure AMD, restore established macular damage or replace treatment for active wet disease. Cochrane’s evidence concerns slowing progression in selected stages. A supplement may be part of the plan while injections address active leakage, but the purposes differ. Continue the monitoring and treatment recommended for your retinal findings and report new symptoms promptly. [6][7]
Anti-VEGF injections are the main treatment for active wet AMD. AAO guidance explains that early detection and prompt treatment improve the outlook. The medicine reduces signals involved in leakage and abnormal vessel growth; it does not rebuild all damaged tissue. Ask what benefit is realistic and how vision and retinal activity will be monitored during the course. [4][15]
They can improve sight in some eyes and help maintain vision, but improvement is not guaranteed. Cochrane supports anti-VEGF treatment while noting limitations in comparisons and rare-harm estimates. The result depends on active disease, existing damage and other eye problems. Stabilising vision can be a valuable outcome, so discuss your treatment goal rather than expecting a particular trial average. [5]
A course and continuing monitoring are commonly needed; the number and interval depend on retinal activity and response. AAO describes ongoing assessment of wet AMD rather than a universal fixed course. Feeling better does not establish that treatment can stop. Tell the team about difficulties attending so the practical plan can be discussed before visits are missed. [4]
Not usually; wet-AMD treatment targets abnormal vessel growth and leakage, whereas atrophy is tissue loss with a different management discussion. AAO reviews these conditions separately. Newer treatments must be considered on their own evidence, risks and availability. Do not assume that an injection offered for another person’s diagnosis is appropriate for your eye or available through the same service. [4]
Check each eye separately, wearing reading glasses if normally used and keeping your gaze on the central dot. AAO advises a daily check for changes in the lines or areas of the grid. Ask your eye-care professional to demonstrate a suitable grid. The web example is educational and does not provide a calibrated diagnosis or replace your monitoring plan. [16]
No; a grid helps notice some changes but does not rule out every problem or replace retinal assessment. NICE recommends reporting new symptoms and using appropriate monitoring for the type of AMD. Seek advice if reading or central vision changes even when the example grid seems unchanged, and keep the reviews recommended by your eye-care team. [3][16]
No; it demonstrates an example of central disturbance, not a forecast or a measure of your macular damage. AMD experiences vary, and AAO bases care on examination and appropriate imaging. The slider has no clinical scale. Use it to understand the idea of central loss, and seek assessment for your own symptoms rather than comparing them with an overlay. [4]
Yes; low-vision assessment can help you choose magnification, lighting and reading methods that suit your remaining sight. NHS information includes support for living with AMD, not just medical treatment. Ask for help when tasks become difficult, including while receiving injections. Suitable aids and training depend on the task and your vision rather than one device working for everyone. [14]
Some people with sight loss see images, patterns or shapes that are not present. NICE includes Charles Bonnet syndrome in AMD information, but new experiences should still be discussed with a clinician. Explain what you see and any other symptoms. Assessment can consider the cause and support needed rather than assuming that every hallucination is due to the macula. [3]
New central distortion or a grey patch needs prompt eye-care advice; sudden major loss, a curtain or a painful red eye needs urgent assessment. NHS information distinguishes these warning symptoms from ordinary gradual AMD changes. After an injection, worsening pain or reduced vision also needs urgent contact. If the treating team is unavailable, attend an emergency department rather than waiting. [13][15]
